View Post

Completion Axillary Lymph Node Dissection to Select Adjuvant Treatment in Breast Cancer and Associated Impairment of Arm Function

In In The News by Barbara Jacoby

By: Matthew Stenger From: ascopost.com In an analysis involving the phase III SENOMAC trial reported in The Lancet Oncology, de Boniface et al found that the use of completion axillary lymph node dissection (cALND) to identify pN2-3 status (at least four nodal metastases) in patients with breast cancer, and thus qualification for adjuvant CDK4/6 inhibitor treatment, was associated with a …